AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.

Axsome Therapeutics reports 66% Q4 revenue growth, blockbuster potential for Auvelity, and robust pipeline progress with 3 NDA filings and key ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...

Good morning, and welcome to the Axsome Therapeutics Fourth Quarter and Full Year 2024 Conference Call. Currently, all participants are in a listen-only mode. Later, there will be a ...

With a new product announcement coming on Wednesday, investors might be wondering: Is Apple stock a buy right now?

A woman has been arrested on suspicion of driving under the influence after she was involved in a crash that claimed the life ...

Alvotech (NASDAQ:ALVO) and Teva Pharmaceuticals (NYSE:TEVA) said on Tuesday that the U.S. FDA has accepted for review a ...

Declares Dividend Increase for 69th Consecutive YearProvides 2025 Outlook Fourth Quarter 2024 Highlights Sales of $5.8 billionDiluted EPS of $0.96Adjusted Diluted EPS of $1.61Full-Year 2024 Highlights ...

Inc. (Stock code: 300725.SZSE) has announced the official launch of its commercial GMP Workshop 503 (W503) at PharmaBlock Zhejiang. The new workshop significantly enhances production capacity and ...